Grant Duncan Stewart

TERRA is a foundation model for spatial transcriptomics that predicts tissue behavior under perturbation and identifies multi-scale biological insights across tissues.

This paper presents a network medicine framework integrating multi-modal data to identify therapeutic targets in clear cell renal cell carcinoma, recovering established targets and predicting five candidates, with ENO2 inhibition showing the strongest anti-tumour effect.

This study shows SET1B maintains HIF activity in ccRCC, correlates with disease progression, and is a target for HIF-2 inhibitors.

This study identifies HIF1A as a key inhibitor of VHL null cell fitness and shows that combined VHL/HIF1A inactivation can confer resistance to PROTAC-based therapies.

The paper assesses neoadjuvant axitinib response in RCC with VTT using multiparametric analysis and identifies angiogenic and immune predictors of treatment response.

The paper traces the origin of four synchronous renal tumours in a child to an early embryonic MTOR mutation, showing its role in tumour development and clinical implications.

A multi-regional single-cell study of kidney tumours reveals clonotypic heterogeneity, immune cell exhaustion, and potential therapeutic targets through transcriptomic and exomic analysis.